Shanghai Haohai Biological Tech Co (688366) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Haohai Biological Tech Co (688366) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥109.13 Million ≈ $15.97 Million USD) by net assets (CN¥5.88 Billion ≈ $861.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shanghai Haohai Biological Tech Co net asset quality index to measure how much of total assets are equity-financed.
Shanghai Haohai Biological Tech Co - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Shanghai Haohai Biological Tech Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shanghai Haohai Biological Tech Co (688366) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Shanghai Haohai Biological Tech Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Haohai Biological Tech Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JOST Werke AG
XETRA:JST
|
0.081x |
|
Telsys
TA:TLSY
|
0.284x |
|
Usinas Siderúrgicas de Minas Gerais S.A
SA:USIM3
|
0.016x |
|
Infund Holding Co Ltd
SHE:002141
|
0.075x |
|
SG Fleet Group Ltd
AU:SGF
|
-0.064x |
|
Lingda Group Co Ltd
SHE:300125
|
-0.021x |
|
Zhejiang Zhengguang Industrial Co. Ltd.
SHE:301092
|
N/A |
|
Arctech Solar Holding Co Ltd
SHG:688408
|
0.068x |
Annual Cash Flow Conversion Efficiency for Shanghai Haohai Biological Tech Co (2012–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Haohai Biological Tech Co from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see Shanghai Haohai Biological Tech Co market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥5.92 Billion ≈ $865.85 Million |
CN¥648.57 Million ≈ $94.91 Million |
0.110x | +3.96% |
| 2023-12-31 | CN¥6.02 Billion ≈ $880.52 Million |
CN¥634.45 Million ≈ $92.84 Million |
0.105x | +169.06% |
| 2022-12-31 | CN¥5.90 Billion ≈ $863.70 Million |
CN¥231.30 Million ≈ $33.85 Million |
0.039x | -30.62% |
| 2021-12-31 | CN¥6.06 Billion ≈ $886.81 Million |
CN¥342.29 Million ≈ $50.09 Million |
0.056x | +23.58% |
| 2020-12-31 | CN¥5.73 Billion ≈ $839.10 Million |
CN¥262.07 Million ≈ $38.35 Million |
0.046x | -25.95% |
| 2019-12-31 | CN¥5.65 Billion ≈ $827.26 Million |
CN¥348.91 Million ≈ $51.06 Million |
0.062x | -39.50% |
| 2018-12-31 | CN¥3.84 Billion ≈ $561.25 Million |
CN¥391.28 Million ≈ $57.26 Million |
0.102x | +0.12% |
| 2017-12-31 | CN¥3.37 Billion ≈ $492.65 Million |
CN¥343.06 Million ≈ $50.20 Million |
0.102x | +19.56% |
| 2016-12-31 | CN¥2.99 Billion ≈ $436.93 Million |
CN¥254.49 Million ≈ $37.24 Million |
0.085x | -15.39% |
| 2015-12-31 | CN¥2.67 Billion ≈ $390.04 Million |
CN¥268.51 Million ≈ $39.29 Million |
0.101x | -57.85% |
| 2014-12-31 | CN¥594.16 Million ≈ $86.94 Million |
CN¥141.99 Million ≈ $20.78 Million |
0.239x | -11.33% |
| 2013-12-31 | CN¥545.05 Million ≈ $79.76 Million |
CN¥146.91 Million ≈ $21.50 Million |
0.270x | -10.48% |
| 2012-12-31 | CN¥393.33 Million ≈ $57.56 Million |
CN¥118.42 Million ≈ $17.33 Million |
0.301x | -- |
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more